Stifel Upgrades Alkermes
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a regimen that works.
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...
BofA analyst Jason Gerberry lowered the firm’s price target on Alkermes (ALKS) to $28 from $29 and keeps a Neutral rating on the shares. The company reported a relatively in-line Q3 and ...
Greetings and welcome to the Alkermes' Third Quarter 2024 Financial Results Conference Call. My name is Maria and I'll be your operator for today's call. All participant lines will be placed on ...
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback